Trial · NCT07893730
Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches
NCT07893730, Phase 2, Not yet recruiting, University College Cork
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches. Trials, record NCT07893730. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893730
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches
- NCT number
- NCT07893730
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 50 participants, estimated
- Lead sponsor
- University College Cork
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
- Interventions
- Liquid biopsy next generation sequencing
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Frequency of Genomic Alterations | Baseline through to study completion, an average of 2 years | The number of genomic alterations detected |
| Primary | Relative proportion of genomic alterations | Baseline through to study completion, an average of 2 years | The relative proportion of genomic alterations |
| Secondary | Concordance of tissue genomic profiling with plasma genomic profiling | Baseline through to study completion, an average of 2 years | To assess the concordance of liquid biopsy plasma genomic profiling compared to tumour-tissue genomic profiling |
| Secondary | Clinical Actionability of Detected Genomic Alterations | Baseline through to study completion, an average of 2 years | Actionability classified using the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT); classified either Tier I, II, III, IV, V or X |
| Secondary | Clinical Actionability of Detected Genomic Alterations | Baseline through to study completion, an average of 2 years | Actionability measured by treatment access via clinical trial |
| Secondary | Clinical Actionability of Detected Genomic Alterations | Baseline through to study completion, an average of 2 years | Actionability measured by treatment access via expanded access programme eligibility |
| Secondary | Clinical Actionability of Detected Genomic Alterations | Baseline through to study completion, an average of 2 years | Actionability measured by treatment access via standard of care |
| Secondary | Overall survival | Measured at study completion; 2 years after enrolment | Time (in days) from enrolment to death from any cause |
| Secondary | Time to Next Treatment | Baseline through to study completion, an average of 2 years | Time (in days) from enrolment to commencement of the next line of treatment |
| Other | Genomic Profiling Turnaround Time | At each liquid biopsy sample collection | Time in days from ordering plasma genotyping to reporting results, and comparison with tissue-genotyping turnaround time where paired results are available |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893730
GET https://conductscience.org/api/trials/v1/NCT07893730/registered